Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.80 +0.08 (+0.30%)
Official Closing Price Updated: 7:00 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,360,234
Open 26.65
Bid (Size) 26.81 (1)
Ask (Size) 26.84 (27)
Prev. Close 26.72
Today's Range 26.36 - 26.81
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool

Performance

YTD
+0.71%
+0.71%
1 Month
+6.14%
+6.14%
3 Month
-7.84%
-7.84%
6 Month
-7.90%
-7.90%
1 Year
-5.37%
-5.37%

More News

Read More
Investing $5,000 Just Once in These 3 Ultra-High-Yielding Stocks Could Earn You $320 in Passive Income Every Year
Via The Motley Fool
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Via Benzinga
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
Via Benzinga
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Is Pfizer Stock Undervalued at Current Prices?
Via The Motley Fool
Should You Buy Pfizer Stock Right Now in 2025?
Via The Motley Fool
Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
Via MarketBeat
Topics Stocks
Exposures US Equities
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Via Benzinga
Topics ETFs
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
Via Benzinga
Exposures Product Safety
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Via The Motley Fool
Investing $50,000 in Each of These 5 Stocks Could Make You Nearly $17,500 in Passive Income in 2025
Via The Motley Fool
Warren Buffett's Warning to Wall Street Reached Deafening Proportions in 2024. Here's What to Do as 2025 Gets Started.
Via The Motley Fool
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study
Via Benzinga
Exposures COVID-19
25 Top Dividend Stocks to Buy and Hold in 2025
Via The Motley Fool
Time to Dump or Double Up on SCHD?
Via The Motley Fool
AskSlim Market Week - Friday, Jan. 3
Via Talk Markets
Topics Futures Stocks / Equities
3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.